RBC Capital analyst Sean Dodge maintained a Hold rating on Health Catalyst (HCAT – Research Report) on February 23 and set a price target of $8.00. The company’s shares closed last Friday at $7.78.
According to TipRanks, Dodge is an analyst with an average return of -5.3% and a 42.47% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Evolent Health, R1 RCM, and Catalent.
In addition to RBC Capital, Health Catalyst also received a Hold from Stifel Nicolaus’s David Grossman in a report issued on February 23. However, today, Wells Fargo maintained a Buy rating on Health Catalyst (NASDAQ: HCAT).
See Insiders’ Hot Stocks on TipRanks >>
Based on Health Catalyst’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $75.08 million and a GAAP net loss of $30.31 million. In comparison, last year the company earned a revenue of $69.16 million and had a GAAP net loss of $35.78 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- Health Catalyst price target lowered to $15 from $17 at Piper Sandler
- Health Catalyst price target lowered to $11 from $12 at Canaccord
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst sees FY24 revenue $304M-$312M, consensus $324.49M
- Health Catalyst sees Q1 revenue $72.5M-$76.5M, consensus $78.99M
